December 3, 2010 – The U.S. Food and Drug Administration (FDA) has given conditional approval for an Investigational Device Exception (IDE) application for a system for treating coronary artery disease. The pivotal trial will look at the Tryton Side Branch Stent.

December 3, 2010 – For the first time, data has shown that cardiac resynchronization therapy (CRT) is cost-effective in mildly symptomatic heart failure (HF) patients. Data from an economic sub-study of the REVERSE trial was published in the European Heart Journal.

November 30, 2010 – The U.S. Food and Drug Administration (FDA) has given 510(k) clearance for a suite of clinical applications that is directly integrated into PACS and cardiovascular systems. FujiFilm Medical’s Synapse 3D is vendor neutral, multi-modality capable, and can be used with virtually any advanced imaging system.

November 30, 2010 – New clinical and reporting capabilities have been added to a cardiovascular image and information system (CVIS). Version 4.0.5 of Synapse Cardiovascular, by FujiFilm Medical Systems, now features 3-D and intelligent structured reporting (ISR), enabling faster creation of consistent, high-quality echocardiography reports. Synapse 3D

November 29, 2010 – Independent research firm Frost and Sullivan has given TeraRecon the North American Growth Leadership of the Year award in Advanced Visualization and Clinical Applications. This is the sixth time in the past 10 years that Frost and Sullivan has given the company an award. The company also received the European Company of the Year award for medical imaging.

November 24, 2010 – A new advanced visualization and analysis software suite has passed a detailed evaluation and testing process and is now available for sale. The Vitrea Enterprise Suite version 6.0, from Vital Images, has achieved VMware Ready status and is now listed on the VMware Partner Product Catalog.

November 24, 2010 – Data from the PICTURE trial showed that an insertable cardiac monitor led to diagnosis and treatment for 78 percent of patients who experienced a recurrent syncopal (fainting) event during the study. The Reveal family of insertable cardiac monitors, by Medtronic, also showed that 75 percent of those diagnosed were shown to have a cardiac cause of their syncopal event.

November 24, 2010 – Results for a trial comparing a drug-eluting stent to balloon angioplasty and bare metal stenting in treating restenosis after angioplasty were announced at the VEITHsymposium. The Zilver PTX drug-eluting stent met the trial's 12-month primary endpoints.

The stent has CE mark approval in Europe for the superficial femoral artery.

November 24, 2010 – Researchers at Northwestern are utilizing a patient’s own stem cells to regenerate heart and vascular tissue, offering a potential new treatment for cardiovascular disease. Northwestern Medicine is the lead site for a study examining stem cell transplantation as treatment for critical limb ischemia.

November 24, 2010 – Cardiologists and primary care physicians now perceive AstraZeneca's Crestor as comparable to Pfizer’s Lipitor in treating and reducing mortality in dyslipidemia patients, according to a survey by Decision Resources.

This finding has changed from Decision Resources' 2009 analysis in which surveyed cardiologists viewed Lipitor as significantly better.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now